-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 26, the Guangdong Provincial Pharmaceutical Exchange Center announced the new products (third batch) newly approved for listing on the third-party drug electronic trading platform of Guangdong Province and the notice of the prices to be listed on the Internet, and disclosed the prices of 6 new drugs
.
What attracts people's attention is that the Akilunza injection produced by Fosun Kate is listed, and the price to be listed on the Internet is officially disclosed for the first time, which is 1.
2 million yuan per injection
.
Since September this year, the Guangdong Pharmaceutical Delivery Center has issued three batches of notices on the proposed online prices of new products, a total of 31 drugs.
The provincial platform will promptly list the prices of related drugs after the prices are confirmed.
Medical institutions can follow the clinical needs.
Purchasing through the provincial platform at a bargaining price not higher than the online price
.
From the perspective of the industry, these innovative drugs and star drugs are expected to quickly land in clinical practice.
Some drugs have also entered this year's national medical insurance catalogue negotiations.
With the announcement of prices, they have also provided a reference for medical insurance negotiations
.
The price information announcement form for new products approved for listing in Guangdong (third batch) CAR-T therapy pricing is disclosed This year, many innovative drugs with unique characteristics have been approved for listing
.
CAR-T therapy is naturally a category that has attracted attention.
In June, Fosun Kate targeted CD19 CAR-T Aquilense injection was approved for marketing, becoming China's first CAR-T therapy approved for marketing
.
In September, WuXi Giant Nuo announced that Ruiji Orenxel injection was approved for marketing, becoming the second CAR-T therapy approved for marketing in China
.
According to data, there are as many as 30 CAR-T therapies entering the clinical stage in China
.
The approval of Akilon and Ricky Oron indicates that the domestic CAR-T therapy has officially opened the curtain of commercialization
.
There are also many domestic CAR-T products that will enter the commercialization stage.
Novartis’ Kymriah is in the phase III clinical phase, and Legend Bio’s BCMA CAR-T is in the phase II clinical phase
.
On the one hand, the domestic CAR-T market is showing increasingly fierce competition, repeated targets, and serious product homogeneity
.
On the other hand, due to the complicated manufacturing conditions of CAR-T therapy and high technical personnel requirements, the current treatment costs remain high
.
High treatment costs will naturally lead to limited accessibility, and how to price domestic CAR-T therapies after they are on the market raises concerns
.
In foreign countries, some countries have included related CAR-T therapies into the scope of medical insurance
.
It is worth noting that Akilunzai is on the list of this year's medical insurance preliminary review
.
However, for the 1.
2 million injections of CAR-T therapy, since the National Medical Insurance Catalogue has not yet included a precedent for "high-priced drugs" to be included in medical insurance, it is yet to be tested whether it can be included in medical insurance
.
Regarding whether "sky-priced drugs" can be included in the catalog, the National Medical Insurance Administration has stated that some more expensive drugs have passed the preliminary formal review, which only indicates that the drug meets the application requirements after the preliminary review and is eligible to enter the next adjustment link
.
Whether such drugs can eventually enter the National Medical Insurance Drug List must be subject to rigorous review including economics.
Exclusive drugs must undergo price negotiations, and only those who have successfully negotiated can enter the list
.
In this regard, there are also opinions that due to the high price, it is expected that CAR-T treatment may still be mainly self-funded for a period of time
.
In addition to CAR-T therapy, Guangdong also announced the proposed online prices of several innovative drugs.
For example, Zai Lab’s repetitinib tablets are 1108.
86 yuan per tablet; Haizheng Pharmaceutical’s Haizheng Pharmaceutical Co.
, Ltd.
has attracted attention.
Bomebu tablets are 8.
47 yuan/piece
.
After sorting out, it is found that Guangdong has released information on the prices of three batches of new products to be listed on the Internet, including many star drugs
.
Take Novo Nordisk's smeglutide injection as an example.
The price is 1120 yuan each.
This product is also on the preliminary review list of this year's National Medical Insurance Catalog
.
As a new type of diabetes treatment drugs, GLP-1 receptor agonists have been attracting market attention
.
At the end of April this year, smeglutide injection was approved for marketing and formally joined the "war" in the Chinese hypoglycemic drug market
.
At present, 8 models of GLP-1 have been approved for marketing in China, 4 of which are short-acting products and 4 are long-acting products
.
Liraglutide was the first to enter the medical insurance catalog in 2017, and in 2019, risenatide and exenatide were included in the medical insurance catalog
.
In the 2020 version of the medical insurance catalogue, the negotiation of dulaglutide, polyethylene glycol loxenatide and benaglutide was successful
.
So far, 6 GLP-1 models have been included in the medical insurance catalog
.
Currently, Eli Lilly's dulaglutide and Novo Nordisk's smeglutide injection are in a period of rapid growth
.
Dulaglutide has global sales of US$5.
068 billion in 2020, ranking first in sales
.
In 2020, the global sales of smegaglutide injection increased by 88.
8% compared with 2019, reaching 21.
211 billion Danish kroner (3.
45 billion US dollars), showing a trend of catching up
.
At this point, dulaglutide and smeglutide will compete for the first place in the GLP-1 market
.
Since dulaglutide has entered the medical insurance, whether smeglutide injection can enter the medical insurance in the first year of listing has become the key to the growth of the Chinese market
.
Many domestic innovative pharmaceutical companies have also announced their prices
.
For example, BeiGene's pamidalicapsule is 116.
66 yuan/cap; Rongchang Biological's tetaxel for injection is 2,586 yuan/bottle, and vedicutumab for injection is 13,500 yuan/bottle
.
As a hot drug, ADC drugs have ushered in an outbreak period in the past two years.
In addition to Rongchang Biological’s Weidixituzumab for injection, there are two imported ADC drugs that have entered the Chinese market, namely Roche’s Enmetril for injection.
Tocilizumab, Takeda's vebutuximab
.
Whether ADC drugs can enter medical insurance this year, and their negotiated prices will form a reference for follow-up products
.
Publicity form of price information for new products approved for listing in Guangdong (first batch) Publicity form of price information for new products approved for listing on Guangdong Internet (second batch)
.
What attracts people's attention is that the Akilunza injection produced by Fosun Kate is listed, and the price to be listed on the Internet is officially disclosed for the first time, which is 1.
2 million yuan per injection
.
Since September this year, the Guangdong Pharmaceutical Delivery Center has issued three batches of notices on the proposed online prices of new products, a total of 31 drugs.
The provincial platform will promptly list the prices of related drugs after the prices are confirmed.
Medical institutions can follow the clinical needs.
Purchasing through the provincial platform at a bargaining price not higher than the online price
.
From the perspective of the industry, these innovative drugs and star drugs are expected to quickly land in clinical practice.
Some drugs have also entered this year's national medical insurance catalogue negotiations.
With the announcement of prices, they have also provided a reference for medical insurance negotiations
.
The price information announcement form for new products approved for listing in Guangdong (third batch) CAR-T therapy pricing is disclosed This year, many innovative drugs with unique characteristics have been approved for listing
.
CAR-T therapy is naturally a category that has attracted attention.
In June, Fosun Kate targeted CD19 CAR-T Aquilense injection was approved for marketing, becoming China's first CAR-T therapy approved for marketing
.
In September, WuXi Giant Nuo announced that Ruiji Orenxel injection was approved for marketing, becoming the second CAR-T therapy approved for marketing in China
.
According to data, there are as many as 30 CAR-T therapies entering the clinical stage in China
.
The approval of Akilon and Ricky Oron indicates that the domestic CAR-T therapy has officially opened the curtain of commercialization
.
There are also many domestic CAR-T products that will enter the commercialization stage.
Novartis’ Kymriah is in the phase III clinical phase, and Legend Bio’s BCMA CAR-T is in the phase II clinical phase
.
On the one hand, the domestic CAR-T market is showing increasingly fierce competition, repeated targets, and serious product homogeneity
.
On the other hand, due to the complicated manufacturing conditions of CAR-T therapy and high technical personnel requirements, the current treatment costs remain high
.
High treatment costs will naturally lead to limited accessibility, and how to price domestic CAR-T therapies after they are on the market raises concerns
.
In foreign countries, some countries have included related CAR-T therapies into the scope of medical insurance
.
It is worth noting that Akilunzai is on the list of this year's medical insurance preliminary review
.
However, for the 1.
2 million injections of CAR-T therapy, since the National Medical Insurance Catalogue has not yet included a precedent for "high-priced drugs" to be included in medical insurance, it is yet to be tested whether it can be included in medical insurance
.
Regarding whether "sky-priced drugs" can be included in the catalog, the National Medical Insurance Administration has stated that some more expensive drugs have passed the preliminary formal review, which only indicates that the drug meets the application requirements after the preliminary review and is eligible to enter the next adjustment link
.
Whether such drugs can eventually enter the National Medical Insurance Drug List must be subject to rigorous review including economics.
Exclusive drugs must undergo price negotiations, and only those who have successfully negotiated can enter the list
.
In this regard, there are also opinions that due to the high price, it is expected that CAR-T treatment may still be mainly self-funded for a period of time
.
In addition to CAR-T therapy, Guangdong also announced the proposed online prices of several innovative drugs.
For example, Zai Lab’s repetitinib tablets are 1108.
86 yuan per tablet; Haizheng Pharmaceutical’s Haizheng Pharmaceutical Co.
, Ltd.
has attracted attention.
Bomebu tablets are 8.
47 yuan/piece
.
After sorting out, it is found that Guangdong has released information on the prices of three batches of new products to be listed on the Internet, including many star drugs
.
Take Novo Nordisk's smeglutide injection as an example.
The price is 1120 yuan each.
This product is also on the preliminary review list of this year's National Medical Insurance Catalog
.
As a new type of diabetes treatment drugs, GLP-1 receptor agonists have been attracting market attention
.
At the end of April this year, smeglutide injection was approved for marketing and formally joined the "war" in the Chinese hypoglycemic drug market
.
At present, 8 models of GLP-1 have been approved for marketing in China, 4 of which are short-acting products and 4 are long-acting products
.
Liraglutide was the first to enter the medical insurance catalog in 2017, and in 2019, risenatide and exenatide were included in the medical insurance catalog
.
In the 2020 version of the medical insurance catalogue, the negotiation of dulaglutide, polyethylene glycol loxenatide and benaglutide was successful
.
So far, 6 GLP-1 models have been included in the medical insurance catalog
.
Currently, Eli Lilly's dulaglutide and Novo Nordisk's smeglutide injection are in a period of rapid growth
.
Dulaglutide has global sales of US$5.
068 billion in 2020, ranking first in sales
.
In 2020, the global sales of smegaglutide injection increased by 88.
8% compared with 2019, reaching 21.
211 billion Danish kroner (3.
45 billion US dollars), showing a trend of catching up
.
At this point, dulaglutide and smeglutide will compete for the first place in the GLP-1 market
.
Since dulaglutide has entered the medical insurance, whether smeglutide injection can enter the medical insurance in the first year of listing has become the key to the growth of the Chinese market
.
Many domestic innovative pharmaceutical companies have also announced their prices
.
For example, BeiGene's pamidalicapsule is 116.
66 yuan/cap; Rongchang Biological's tetaxel for injection is 2,586 yuan/bottle, and vedicutumab for injection is 13,500 yuan/bottle
.
As a hot drug, ADC drugs have ushered in an outbreak period in the past two years.
In addition to Rongchang Biological’s Weidixituzumab for injection, there are two imported ADC drugs that have entered the Chinese market, namely Roche’s Enmetril for injection.
Tocilizumab, Takeda's vebutuximab
.
Whether ADC drugs can enter medical insurance this year, and their negotiated prices will form a reference for follow-up products
.
Publicity form of price information for new products approved for listing in Guangdong (first batch) Publicity form of price information for new products approved for listing on Guangdong Internet (second batch)
